Prophylactic quadrivalent human papillomavirus (types 6, 11, 16, and 18) L1 virus-like particle vaccine in young women: A randomised double-blind placebo-controlled multicentre phase II efficacy trial

Luisa L. Villa, Ronaldo L.R. Costa, Carlos A. Petta, Rosires P. Andrade, Kevin A. Ault, Anna R. Giuliano, Cosette M. Wheeler, Laura A. Koutsky, Christian Malm, Matti Lehtinen, Finn Egil Skjeldestad, Sven Eric Olsson, Margareta Steinwall, Darron R. Brown, Robert J. Kurman, Brigitte M. Ronnett, Mark H. Stoler, Alex Ferenczy, Diane M. Harper, Gretchen M. TammsJimmy Yu, Lisa Lupinacci, Radha Railkar, Frank J. Taddeo, Kathrin U. Jansen, Mark T. Esser, Heather L. Sings, Alfred J. Saah, Eliav Barr

Research output: Contribution to journal › Article › peer-review

1070 Scopus citations

Fingerprint

Dive into the research topics of 'Prophylactic quadrivalent human papillomavirus (types 6, 11, 16, and 18) L1 virus-like particle vaccine in young women: A randomised double-blind placebo-controlled multicentre phase II efficacy trial'. Together they form a unique fingerprint.

Medicine & Life Sciences